Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

9.095 +0.005 (+0.06%)
Streaming Delayed Price Updated: 9:33 AM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,119
Open 9.085
Bid (Size) 9.080 (300)
Ask (Size) 9.140 (200)
Prev. Close 9.090
Today's Range 8.995 - 9.124
52wk Range 3.860 - 9.150
Shares Outstanding 54,576,156
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Telix Appoints David Gill as Chair
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus Q2 Earnings Call Highlights ↗
Evolus (NASDAQ:EOLS) reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid... 
Via MarketBeat
Topics Earnings

Performance

YTD
+35.3%
+35.3%
1 Month
+50.3%
+50.3%
3 Month
+39.5%
+39.5%
6 Month
+112.0%
+112.0%
1 Year
+21.3%
+21.3%

More News

Read More
Evolus (NASDAQ:EOLS) Tops Q2 EPS Estimates and Raises Revenue Guidance, Shares Gain 5.7% ↗
Via Chartmill
News headline image
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
From Evolus
Via Business Wire
News headline image
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
From Evolus
Via Business Wire
Evolus Inc (NASDAQ:EOLS) Q1 2026 Earnings: Narrowed Loss and Positive EBITDA Drive After-Hours Rally ↗
Via Chartmill
Evolus Inc (NASDAQ:EOLS) Reports Q4 2025 Earnings Beat and Path to 2026 Profitability ↗
Via Chartmill
Topics Earnings
News headline image
Evolus to Report Second Quarter Financial Results on August 5, 2026
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
From Evolus
Via Business Wire
News headline image
Evolus to Participate in The Jefferies Global Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
From Evolus
Via Business Wire
News headline image
Evolus (EOLS) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics World Trade
News headline image
Evolus (EOLS) Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
From Evolus
Via Business Wire
News headline image
Evolus to Report First Quarter Financial Results on May 4, 2026
From Evolus
Via Business Wire
News headline image
Telix Appoints David Gill as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
From Evolus
Via Business Wire
News headline image
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Evolus
Via Business Wire
News headline image
Why Evolus Stock Soared Today ↗
Via The Motley Fool
What's going on in today's session ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
News headline image
Evolus (EOLS) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026
From Evolus
Via Business Wire

Frequently Asked Questions

Is Evolus, Inc. - Common Stock publicly traded?
Yes, Evolus, Inc. - Common Stock is publicly traded.
What exchange does Evolus, Inc. - Common Stock trade on?
Evolus, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Evolus, Inc. - Common Stock?
The ticker symbol for Evolus, Inc. - Common Stock is EOLS on the Nasdaq Stock Market
What is the current price of Evolus, Inc. - Common Stock?
The current price of Evolus, Inc. - Common Stock is 9.095
When was Evolus, Inc. - Common Stock last traded?
The last trade of Evolus, Inc. - Common Stock was at 09/01/26 09:33 AM ET
What is the market capitalization of Evolus, Inc. - Common Stock?
The market capitalization of Evolus, Inc. - Common Stock is 496.37M
How many shares of Evolus, Inc. - Common Stock are outstanding?
Evolus, Inc. - Common Stock has 496M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.